Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application DOI Creative Commons

J. Nandhini,

Karthikeyan Elumalai

Chronic Diseases and Translational Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the course but only treat its manifestations. This limitation brought attention need treatments that modify amyloid‐beta (Aβ) tau pathology of disease. One recent advancement in AD is donanemab, a monoclonal antibody intended clear Aβ plaques brain. It targets pyroglutamyl(3)‐Aβ protein (3–42) remove deposits alter course. review explores timeline donanemab use from discovery clinical use. The pharmacodynamics pharmacokinetics drug are discussed along with typical suboptimal preclinical trial results terms efficacy, safety, tolerability. Thus, more effective than donepezil rivastigmine removing improving cognition. At same time, it devoid safety concerns majority amyloid‐targeted medicines. control end after plaque cleaning unique selling point some patients, making attractive. innovation development practice representation role field translational medicine practical application new knowledge AD.

Language: Английский

Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management DOI
Jinjin Pei,

Ranil Vikraman Kumarasamy,

Selvaraj Jayaraman

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102665 - 102665

Published: Jan. 1, 2025

Language: Английский

Citations

3
Curcumin reverses cognitive deficits through promoting neurogenesis and synapse plasticity via the upregulation of PSD95 and BDNF in mice DOI Creative Commons

Gaifen Li,

Qiong Wu, Chao Wang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 7, 2025

Following prolonged exposure to hypoxic conditions, for example, due ascent high altitude, aging or stroke, cognitive deficits can develop. The exact nature and genesis of hypoxia-induced remain unresolved. Curcumin has been reported stimulate neurogenesis reduce neuronal degeneration. This study aimed investigate the effect curcumin on in hypoxic-brain injury mice its potential mechanism. Eight-week-old male C57BL/6J were normobaric-hypoxia (13%O2) 14 days establish models. Morris water maze novel object recognition used detect function each mouse. Immunofluorescence assays, including Fluoro-Jade C (FJC) bromodeoxyuridine (BrdU), degeneration neurogenesis. Thy1-YFP transgenic synapse plasticity. Our results showed that administration rescued impaired cognition mice, shown as enhanced BrdU+ dendritic spine hippocampus. At molecular level, was found promote expression brain-derived neurotrophic factor (BDNF) postsynaptic density protein 95 (PSD95). primary hippocampal neuron detection could growth. In conclusion, our indicates curcumin, increased BDNF PSD95 contacted with interneurons, salvaged interneurons may normalize ambient neuroplasticity, resulting preservation processes well contributing improve performance.

Language: Английский

Citations

1
Nanotechnology for Healthcare: Plant-Derived Nanoparticles in Disease Treatment and Regenerative Medicine DOI Creative Commons
Arun Karnwal,

Amar Yasser Jassim,

Ameer A. Mohammed

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1711 - 1711

Published: Dec. 18, 2024

Nanotechnology has revolutionised biomedical research, offering innovative healthcare solutions. Plant-based nanotechnology is emerging as a sustainable alternative, minimising environmental impacts and enhancing therapeutic effectiveness. This paper explores the potential of plant-derived nanoparticles (PNPs) in medicine, highlighting their biocompatibility, multifunctionality, eco-friendliness. PNPs, synthesised through green methods, have demonstrated promising applications drug delivery, cancer therapy, antimicrobial treatments, tissue regeneration. Their unique properties, such high surface area bioactive components, enable improved targeting, controlled release, reducing side effects treatment efficacy. Additionally, compounds’ inherent antioxidant retained within platinum (PNPs), present opportunities for combating resistance promoting wound healing. Despite potential, challenges remain standardising PNP synthesis, ensuring consistency, scaling up production industrial applications. review emphasises need further research on toxicity, regulatory frameworks to fully harness capabilities clinical commercial represents promising, greener alternative advancing solutions, aligning with global sustainability goals.

Language: Английский

Citations

7
Stable emulsion produced by thermal modified coconut (Cocos nucifera L.) globulins-xanthan gum for protection of curcumin DOI
Jingrong Ma, Rongrong He, Yongchuan Chai

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 302, P. 140653 - 140653

Published: Feb. 3, 2025

Language: Английский

Citations

0
Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities DOI Open Access
Md. Ataur Rahman, Maroua Jalouli,

Mahesh Kumar Yadab

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 701 - 701

Published: Feb. 19, 2025

Glioblastoma multiforme (GBM) is a highly malignant brain tumor that has bleak outlook despite existing treatments such as surgery, radiation, and chemotherapy. The utilization of nanoparticles for drug delivery presents promising method by which to improve the effectiveness treatment while reducing harmful effects on entire body. This review examines application in GBM, focusing different types nanoparticles, including lipid-based, polymeric, metallic, those under development. Every variety analyzed its distinct characteristics therapeutic capacity. Lipid-based liposomes solid lipid enhance transport medicines are not soluble water have shown considerable potential preclinical investigations. Polymeric benefits terms controlled release targeted distribution, whereas metallic both therapy imaging. In current we would like emphasize ways medicine delivery, specifically enhancing penetration blood-brain barrier (BBB), targeting tumors, enabling release. Additionally, also discuss clinical discoveries, highlighting achievements obstacles process converting these technologies into effective GBM. study offers thorough examination present status prospects

Language: Английский

Citations

0
Chitosan-Coated Silver Nanourchins for Imatinib Mesylate Delivery: Biophysical Characterization, In-Silico Profiling, and Anti-Colon Cancer Efficacy DOI
Sankha Bhattacharya,

Aalind Joshi,

Vishal Beldar

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

This study investigates the synthesis and characterization of silver nanourchins coated with chitosan (IMT-CS-AgNUs) as a novel platform for delivery imatinib mesylate (IMT) treatment colon cancer. In-silico analysis discovered 10 key metabolites IMT, which have associated respiratory neurotoxic risks. Molecular docking studies showed high affinity binding IMT to critical proteins, including BCL2 (−6.637 kcal/mol), Caspase-6, EGFR, proved its potential therapeutic value. IMT-CS-AgNUs were prepared by ionic gelation, nanoparticles had size 192.98 nm, an entrapment efficiency 85.7%. The FTIR XRD structural confirmed that nanocarriers stable amorphous in nature. In vitro HCT116 cells significantly increased cytotoxicity IC50 0.4 μg/mL; apoptosis 42.5% ROS generation 47.8% when compared only IMT. release drugs from was sustained over 85% 60 h, selectively inhibited pathogenic bacteria without harming beneficial microbes, antiangiogenic activity, is validated through HET-CAM assay. Gene expression analyses there marked downregulation upregulation apoptotic genes. Pharmacokinetic Wistar rats improved bioavailability 1.8, allows targeted drug concentrations lessened systemic toxicity. Thus, development represents potent approach therapy against cancer, providing efficacy, controlled release, added safety.

Language: Английский

Citations

0
Functionalized carbon dots with guanidine salt ionic liquid regulate oxidative damage and amyloid aggregation DOI
Chao Wang, Tongtong Hou, Xu Shao

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 306, P. 141531 - 141531

Published: Feb. 26, 2025

Language: Английский

Citations

0
Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application DOI Creative Commons

J. Nandhini,

Karthikeyan Elumalai

Chronic Diseases and Translational Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the course but only treat its manifestations. This limitation brought attention need treatments that modify amyloid‐beta (Aβ) tau pathology of disease. One recent advancement in AD is donanemab, a monoclonal antibody intended clear Aβ plaques brain. It targets pyroglutamyl(3)‐Aβ protein (3–42) remove deposits alter course. review explores timeline donanemab use from discovery clinical use. The pharmacodynamics pharmacokinetics drug are discussed along with typical suboptimal preclinical trial results terms efficacy, safety, tolerability. Thus, more effective than donepezil rivastigmine removing improving cognition. At same time, it devoid safety concerns majority amyloid‐targeted medicines. control end after plaque cleaning unique selling point some patients, making attractive. innovation development practice representation role field translational medicine practical application new knowledge AD.

Language: Английский

Citations

0